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OBJECTIVES: To assess the long-term cost-effectiveness of various doses of rosuvas-
tatin (R) versus relevant doses of simvastatin (S) (R20 mg versus S40 mg (primary 
analysis), R10 versus S20 and R10 versus S40) in a patient population with high risk 
of cardiovascular events (10-year Framingham CVD risk ≥ 20%). METHODS: A 
Monte Carlo simulation model was developed based on the JUPITER (Justiﬁ cation 
for the Use of statins in Primary prevention: an Intervention Trial evaluating Rosuv-
astatin, NCT00239681) trial ﬁ ndings and includes modeling of cardiovascular events 
and death over the lifetime of patients. The relative efﬁ cacy of S20, S40 and R10 
compared with R20 (as observed in JUPITER) was estimated by computing relative 
10-year Framingham cardiovascular event risks based on reported differences in Total 
Cholesterol/High-Density Lipoprotein cholesterol ratio. Epidemiological data speciﬁ c 
for the Swedish setting were utilized to model post-event mortality and long-term 
overall mortality in event-free patients. Incremental effectiveness was primarily mea-
sured as quality-adjusted life-years (QALYs) gained. Cost-effectiveness was assessed 
based upon direct costs. All effects and costs (in 2008/09 Swedish unit prices) were 
discounted at annual 3%. RESULTS: The model estimated that treating a cohort of 
100,000 patients (66 years, 60% males) with R20 mg avoided 2642 CVD events over 
lifetime compared with S40 mg. This translated into an estimated gain of 9515 years 
in full health (QALYs). The incremental cost per QALY gained was SEK161,712 
(16,434). The cost per QALY gained was SEK228,655 (c23,237) for R10 versus S20, 
and SEK234,932 (c23,875) for R10 versus S40. Probabilistic sensitivity analyses sup-
ported base-case results. CONCLUSIONS: Treatment with rosuvastatin 10 and 20 mg 
is cost-effective compared with relevant doses of simvastatin in the primary prevention 
of CVD for patients with high baseline cardiovascular risk (10-year Framingham CVD 
risk ≥ 20%).
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OBJECTIVES: To assess long-term cost-effectiveness of various doses of rosuvastatin 
(R) versus relevant doses of generic atorvastatin (A) (R20 mg versus A40 mg (primary 
comparison), R10 versus A20 and; R40 versus A80) in patients with a high risk of 
CV events (10-year Framingham CVD risk ≥ 20%). METHODS: A Monte Carlo 
simulation model was developed based on JUPITER (Justiﬁ cation for the Use of statins 
in Primary prevention: an Intervention Trial evaluating Rosuvastatin, NCT00239681) 
trial ﬁ ndings and modeled cardiovascular events and death over the lifetime of 
patients. The relative efﬁ cacy of the A20, A40, A80, R10, and R40 mg compared to 
R20 mg (as observed in JUPITER) were estimated by computing relative 10-year 
Framingham cardiovascular event risks based on reported differences in Total Cho-
lesterol/High-Density Lipoprotein cholesterol ratio. Epidemiological data speciﬁ c for 
the Swedish setting were utilized to model mortality. Incremental effectiveness was 
primarily measured as quality-adjusted life-years (QALYs) gained. Cost-effectiveness 
was assessed based upon direct costs. All effects and costs (2008/09 Swedish unit 
prices) were discounted at annual 3%. An 80% price reduction was assumed for 
generic versus branded statin. RESULTS: The model estimated that treating a cohort 
of 100,000 patients (66 years, 60% males) with R20 avoided 1121 CVD events over 
lifetime compared with atorvastatin 40 mg. This translated into an estimated gain of 
4090 years in full health (QALYs). The estimated incremental cost per QALY gained 
was SEK366,763 (c37,273). This estimate was SEK428,060 (c43,502) for R10 versus 
A20, and SEK582,241 (c59,171) for R40 versus A80. Probabilistic sensitivity analyses 
supported base-case results. CONCLUSIONS: Treatment with rosuvastatin 10 mg, 
20 mg and 40 mg is cost-effective compared with relevant doses of generic atorvastatin 
(20 mg, 40 mg, 80 mg, respectively) for the primary prevention of cardiovascular 
events for patients with high baseline cardiovascular risk (10-year Framingham CVD 
risk ≥ 20%) in Sweden.
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OBJECTIVES: Containing pharmaceutical budgets has encouraged generic prescribing 
policies. Across Europe, many patients have been switched from atorvastatin to 
generic statins, particularly simvastatin, but often at lower therapeutic doses. This 
study sought to estimate the potential clinical and economic effect if policy-induced 
switching to ﬁ rst generation statins occurred in Belgium as per previously observed 
patterns. METHODS: A Markov micro-simulation model was populated with 80 
primary prevention Belgian patients from a 2007 observational study. Risks of ﬁ rst-
onset cardiovascular disease (CVD) were estimated using a calibrated Framingham 
risk equation. With a baseline of January 2010, follow-up was simulated for 20 years. 
Decision analysis estimated the marginal effects of switching all patients from atorv-
astatin (weighted average daily dose [WADD] 20.7 mg) to simvastatin (WADD 
31.6 mg). Dose-speciﬁ c, lipid-modifying effects of the two statins, CVD costs and 
utilities were sourced from published data. Annual discount rates of 3% and 1.5% 
were applied to costs and health effects, respectively. RESULTS: Of the 80 subjects 
on atorvastatin, 23 (28.9%) were predicted to develop CVD over 20 years. In the 
switched-to-simvastatin group, the predicted number was 26 (32.0%), equating to a 
“number needed to harm” of 32. Switching was estimated to lead to a net cost saving 
of c581 per subject, but also a loss of 0.04 QALYs. These equated to an ICER of 
c13,608 per QALY gained (atorvastatin vs. simvastatin). Sensitivity analyses indicated 
the results to be robust. CONCLUSIONS: Our preliminary analyses indicate that there 
would be an increase in the burden of CVD if Belgian patients are switched from 
atorvastatin to generic simvastatin at non-equipotent doses, as has happened in neigh-
bouring countries like The Netherlands. This study highlights the need to consider the 
potential health and health economic impact of population-based switching policies.
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OBJECTIVES: To estimate the cost-effectiveness of rivaroxaban against enoxaparin 
for the prophylaxis of venous thromboembolism (VTE) in patients after total knee 
replacement (TKR) in Slovakia from payer perspective. METHODS: Previously pub-
lished cost-utility model based on results of large randomized controlled trial 
(RECORD 3) has been adapted to Slovakian settings. In RECORD 3, patients received 
12 days prophylaxis with rivaroxaban or enoxaparin. Rivaroxaban reduced total VTE 
(composite: any DVT, non-fatal PE, all-cause mortality) by 49% versus enoxaparin 
after 12 days prophylaxis. The model was divided into three parts: prophylaxis, post-
prophylaxis, and long-term complications. The ﬁ rst two parts represents acute phase 
and were modeled as a decision tree. Third part represents the long-term complications 
and was developed as a Markov model. The ﬁ rst part of the model is populated by 
RECORD 3 trial, while published epidemiological and clinical data estimating the risk 
of further VTE events and post-thrombotic syndrome beyond the trial period were 
used in second and third part of the model. Local cost data was based on published 
price lists, clinical guidelines, product labels and expert opinion. VTE related utilities 
were used from literature. Effectiveness was measured in quality-adjusted life-years 
(QALY). Time horizon was set at 5 years and payers perspective was used. Discount 
rate was 5% per year for costs and effects according to valid Ministry of Health 
(MoH) guidelines for health economic evaluation. One-way and probabilistic sensitiv-
ity analyses were performed. RESULTS: Rivaroxaban produced improved outcomes 
(QALY) and cost savings of c28 per patient versus enoxaparin in Slovakian setting 
(dominance). Probabilistic sensitivity analysis showed dominance of rivaroxaban com-
pared to enoxaparin in more then 99% of cases. CONCLUSIONS: Prophylaxis of 
VTE with rivaroxaban following TKR may improve health outcomes and reduce direct 
medical costs when compared to enoxaparin in Slovakian setting.
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OBJECTIVES: Patients requiring a coronary stent can receive a bare-metal stent (BMS) 
or a drug-eluting stent (DES), but both have their advantages and disadvantages. We 
estimated the potential one-year cost-effectiveness of a test to decide which stent a 
patient should receive based on the risk of restenosis after a BMS implantation. 
METHODS: This study was performed as part of a Dutch large-scale ﬁ ve-year study 
(“Circulating Cells”) now underway to identify blood biomarkers to facilitate the 
prevention and treatment of coronary heart disease. a Markov chain Monte Carlo 
model was developed to estimate costs and effectiveness for three strategies: DES for 
all patients, BMS for all patients, and use of a test (80% sensitivity & 80% speciﬁ city). 
Input values were based on the literature and expert opinion. Costs were calculated 
according to the health care sector perspective. Scenario and sensitivity analyses were 
performed to test the robustness of the results. RESULTS: The DES-for-all strategy 
was the most effective (0.840 QALYs), followed by the test strategy (0.839) and the 
BMS-for-all strategy (0.838). However, it was also more costly (c8189) than the other 
two (test strategy, c7475; BMS, c6905). These results meant high incremental cost-
effectiveness ratios for the test and DES-for-all strategies. Implanting DES in all 
patients would have an important budget impact (c46,000,000) for the The Nether-
lands, given 36,000 interventions annually. Various input parameters had an impor-
tant inﬂ uence on the results, including the sensitivity, speciﬁ city and costs of the test. 
CONCLUSIONS: Both DES and BMS stents are often used for PCIs in the The 
Netherlands. a stratifying test has the potential to reduce costs and still achieve accept-
